Anchor
The blood test revolution in Alzheimer's diagnosis
New CapabilitiesFour FDA-cleared tests, but Medicare still won't cover screening
July 1st, 2026: ASAP Act Stalls; Medicare Screening Gap PersistsNew here? Follow stories to track developments over time. Create a free account to get updates when stories you care about change.
Overview
Updated 3 days agoAlzheimer's diagnosis used to require a $5,000 brain scan or a painful spinal tap. As of August 2026, the FDA has cleared four blood tests for the disease, from Roche's Elecsys pTau217 to C2N's PrecivityAD2, approved for adults as young as 40.
A single blood draw now confirms or rules out the amyloid plaques behind Alzheimer's. Medicare still won't cover the tests for people without symptoms, and the ASAP Act meant to change that has stalled in Congress. That gap matters because 7.2 million Americans have the disease, and drugs like Leqembi and Kisunla slow it only when started early.
Questions about this story
Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.
No questions yet — be the first to ask.
Key Indicators
7.2M
Americans with Alzheimer's
First time prevalence has exceeded 7 million, with projections reaching 13.8 million by 2060
97.9%
Accuracy ruling out disease
Roche-reported negative predictive value for its Elecsys pTau181 test in the FDA clearance trial of 312 participants
$130
Medicare reimbursement per test
CMS finalized this rate after initially proposing $17, making tests viable for labs that serve patients with symptoms
$384B
Annual cost of Alzheimer's care
Projected to reach nearly $1 trillion by 2050 without medical breakthroughs
4
FDA-cleared blood tests
Fujirebio's Lumipulse (May 2025), Roche's Elecsys pTau181 (Oct 2025), Roche's Elecsys pTau217 and C2N's PrecivityAD2 (both Aug 2026)
50%
Alzheimer's cases undiagnosed
Roughly half of Americans living with Alzheimer's or at risk for it have not been diagnosed, per University of Michigan researchers
Voices
Curated perspectives — historical figures and your fellow readers.
Play
Exploring all sides of a story is often best achieved with Play.
Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict.
Log in
Sign Up
Higher or Lower
A number from this story, against one from elsewhere in the news — guess which is bigger, then keep the chain going. 5 rounds, 3 strikes; a miss costs a strike and resets your streak.
Example
Anchor
EU tariff revenue
$52B
Big for this kind of number
Mystery
Pentagon AI contract
?
Round 1
Streak: 0
Mystery
?
Keyboard: ↓/L lower · ↑/H higher
0 pts
Best streak: 0 · Rounds: 0
0 points — sign up to put that on the leaderboard.
Now try on this story
Timeline
The blood test revolution in Alzheimer's diagnosis
Order five events from this story, oldest at top. Each in the right slot scores 1 — neighbours within one slot count too. Your previous result — green ✓ for exact slots, yellow ~ for off by one. Cards now in true chronological order.
Loading puzzle…
Tap 💡 Free hint to lock the oldest into slot 1 — that leaves just four to order. Type pills are clues.
0/5
Exact slot
0/5
Within 1
Sign up to save your score and track a streak across stories.
Now try on this story
Connections
Sixteen names from the news. Find the four hidden groups of four. Four mistakes max.
Loading today's puzzle…
0/4 groups
Mistakes
Sign up to keep a daily streak — a new puzzle lands every day.
Now try on this story
Exit debate?
Your progress in this debate will be lost.
How it works
- 1 Two AI personas square off on this story.
- 2 You predict who'll win each round — correct picks earn XP.
- 3 One crossfire question is yours to fire. Pick it carefully.
Couldn't generate a topic
Select Your Champions
Choose one persona for each side of the debate
DEBATE TOPIC
Choose personas with different perspectives for a more dynamic debate.
SIDE A (PRO)
Select debater for this side:
No debate personas available right now.
SIDE B (CON)
Select debater for this side:
No debate personas available right now.
VS
Get ready to make your prediction...
Round of
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Claim
Evidence
Stakes
Crossfire Answer
Closing Statement
Your Crossfire Question
Generating arguments...
Who's Got This Round?
Make your prediction before the referee scores
The referee scores both sides on
Correct predictions earn +20 XP
· Press 1 or 2 to pick
Evidence
40%
Logic
30%
Detail
20%
Style
10%
Round Results
Your Pick
Not this time
(%)
Overall Score
/10
Your Pick
Not this time
(%)
Overall Score
/10
Set the Crossfire
Pick the question both personas must answer in the final round
Crafting crossfire questions...
Choosing a question earns +10 XP crossfire bonus
🏆
Total XP Earned
Cred Change
Predictions
Debate Oracle! You called every round!
Sharp Instincts! You know your debaters!
The Coin Flip Strategist! Perfectly balanced!
The Contrarian! Bold predictions!
Inverse Genius! Try betting the opposite next time!
XP Breakdown
Base completion
+20 XP
Rounds played ( rounds x 5 XP)
+ XP
Correct predictions ( correct x 20 XP)
+ XP
Crossfire bonus
+10 XP
Accuracy
%
Prediction History
Round
You picked:
✓
✗
Now try on this story
Keep debating to level up your credibility and unlock achievements
People Involved
Jeff Shuren
Director, FDA Center for Devices and Radiological Health
Oversaw approval of four Alzheimer's blood tests
Thomas Schinecker
CEO, Roche
Led development of two FDA-cleared blood tests (pTau181, pTau217)
Maria C. Carrillo
Chief Science Officer, Alzheimer's Association
Pushing for Medicare screening coverage as ASAP Act stalls
Organizations Involved
Roche Diagnostics
Medical Device Manufacturer
Developer of two FDA-cleared Alzheimer's blood tests
Swiss pharmaceutical and diagnostics giant pioneering blood-based Alzheimer's biomarker testing.
Fujirebio Diagnostics
In Vitro Diagnostics Company
Developer of the first FDA-cleared test, now expanding in Europe
Japanese diagnostics company that won FDA clearance for the first Alzheimer's blood test in May 2025.
C2N Diagnostics
Precision Medicine Company
FDA cleared PrecivityAD2 for adults 40 and older (August 2026)
St. Louis-based company pioneering mass spectrometry-based Alzheimer's blood tests.
Eli Lilly and Company
Pharmaceutical company
Partner in diagnostic development and maker of Kisunla
Pharmaceutical giant developing both Alzheimer's treatments and the diagnostics to identify eligible patients.
Centers for Medicare & Medicaid Services
Federal Agency
Covers tests only after symptoms appear; ASAP Act pending
Federal agency whose reimbursement decisions determine whether blood tests become economically viable.
Laboratory Corporation of America
Clinical Laboratory Services
Offering FDA-cleared blood tests nationwide
Major lab operator making Alzheimer's blood tests available at 2,200+ patient service centers.
Quest Diagnostics
Clinical Laboratory Services
Offering blood tests including direct-to-consumer options
Lab giant offering both physician-ordered and controversial direct-to-consumer Alzheimer's tests.
Timeline
January 2018 July 2026
14 events
Latest: July 1st, 2026 · 2 months ago
Showing 8 of 14
Tap a bar to jump to that date
-
ASAP Act Stalls; Medicare Screening Gap Persists
Latest LegislativeMedicare still does not cover Alzheimer's blood tests for people without symptoms. The ASAP Act, which would create a coverage pathway, has not passed as of mid-2026, leaving patients who want early screening to pay $500 to $1,000 per test out of pocket, per ALZRA.
-
Bipartisan ASAP Act Introduced
LegislativeCongress introduces bill creating Medicare pathway for FDA-cleared blood biomarker screening tests.
-
FDA Clears Roche Test for Primary Care
RegulatoryElecsys pTau181 becomes first blood test cleared specifically for primary care use, ruling out disease 97.9% of the time.
-
C2N Submits FDA Application
RegulatoryC2N files first multi-analyte algorithmic blood test using high-resolution mass spectrometry for FDA review.
-
Labcorp Launches Lumipulse Nationwide
CommercialFirst FDA-cleared test becomes available at 2,200+ Labcorp patient service centers across United States.
-
Roche Receives European CE Mark
RegulatoryElecsys pTau181 test receives CE Mark certification, clearing path for European market entry.
-
FDA Clears First Alzheimer's Blood Test
RegulatoryFujirebio's Lumipulse becomes first FDA-cleared blood test, measuring pTau217/Aβ1-42 ratio with 91.7% positive predictive value.
-
Fujirebio Discovers Manufacturing Issues
QualityAt CTAD conference, Fujirebio identifies problems with commercial lots, placing Lumipulse product on quality hold.
-
CMS Finalizes $130 Reimbursement Rate
PolicyAfter proposing just $17, CMS sets $130 Medicare reimbursement, making tests economically viable for labs.
-
FDA Approves Kisunla, Second Anti-Amyloid Drug
TreatmentDonanemab approval intensifies pressure for accessible diagnostics, as drug only works in early-stage disease.
-
Roche-Lilly Test Gets Breakthrough Designation
RegulatoryFDA grants Roche's Elecsys pTau217 test Breakthrough Device designation, expediting review for partnership with Eli Lilly.
-
Quest Launches Controversial Direct-to-Consumer Test
CommercialQuest introduces direct-to-consumer Alzheimer's blood test, sparking debate about testing without physician guidance.
-
FDA Approves Leqembi, First Disease-Modifying Drug
TreatmentLecanemab becomes first therapy proven to slow Alzheimer's cognitive decline, creating urgent need for early diagnostic tools.
-
C2N Receives First Breakthrough Device Designation
RegulatoryFDA grants C2N Diagnostics Breakthrough Device designation for its mass spectrometry-based blood test, beginning the regulatory sprint.
Historical Context
3 moments from history that rhyme with this story — and how they unfolded.
1985-1990
HIV Antibody Test Approval (1985)
FDA approved the first blood test detecting HIV antibodies in March 1985, three years after HIV was identified as the cause of AIDS. The test transformed a death sentence into a manageable chronic disease by enabling early treatment. However, initial rollout faced controversy over false positives, stigma, and questions about testing without available treatments.
Then
Testing initially limited to blood banks and high-risk populations, with significant debate over mandatory testing.
Now
Blood testing became routine medical practice, enabling the antiviral revolution that turned HIV into a manageable condition.
Why this matters now
Like HIV testing, Alzheimer's blood tests arrive alongside new treatments (Leqembi, Kisunla) that work best when disease is caught early—but raise similar questions about testing people when treatments aren't universally accessible.
1994-2012
PSA Test for Prostate Cancer (1994)
FDA approved PSA blood testing for prostate cancer screening in 1994, promising early detection through simple blood draws instead of biopsies. Adoption soared. By 2008, most men over 50 were getting regular PSA tests. However, studies revealed widespread overdiagnosis and overtreatment—many men received aggressive treatment for slow-growing cancers that would never have harmed them.
Then
PSA testing became standard of care, with millions of men screened annually and prostate cancer detection increasing sharply.
Now
In 2012, the US Preventive Services Task Force recommended against routine PSA screening after data showed harms outweighed benefits for most men.
Why this matters now
Cautionary tale for Alzheimer's blood tests: early detection isn't always beneficial if treatments are limited, expensive, or carry significant side effects—and if tests generate false positives causing unnecessary anxiety.
2015-2018
Theranos Blood Testing Scandal (2015-2018)
Theranos claimed revolutionary blood testing technology using fingerprick samples, attracting $700 million in investment and partnerships with Walgreens. Investigative journalism revealed the technology didn't work—tests were inaccurate and the company used traditional machines for most analyses. Founder Elizabeth Holmes was convicted of fraud. The scandal traumatized the blood testing industry.
Then
Theranos collapsed, investors lost hundreds of millions, and regulatory scrutiny of diagnostic startups intensified dramatically.
Now
FDA tightened oversight of laboratory-developed tests; investors became cautious about diagnostic companies; public trust in blood testing innovation damaged.
Why this matters now
The Theranos shadow looms over Alzheimer's blood tests—explaining why FDA demanded rigorous validation, why some experts questioned Quest's direct-to-consumer model, and why Fujirebio's manufacturing issues triggered immediate concern.
Sources
(22)Related Stories
The race to detect cancer from a blood draw
New Capabilities
Updated Aug 13
FDA authorizes first standalone robotic blood-draw device
New Capabilities
Updated 4 days ago
FDA approves Guardant360 Liquid CDx with 100x larger genomic panel
New Capabilities
Updated May 20
First drug engineered to cross the blood-brain barrier wins FDA approval
New Capabilities
Updated May 30
Precision proteomics companies race to commercialize blood-based disease detection
New Capabilities
Updated May 31
Copper drug repairs the brain's waste-clearance pumps in Alzheimer's mice
New Capabilities
Updated Jun 17